UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000053005
Receipt number R000060454
Scientific Title Verification of the effects of test food intake on itchy skin : Placebo-controlled, double-blind, randomized, parallel-group comparison study
Date of disclosure of the study information 2023/12/07
Last modified on 2024/12/02 18:47:58

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Verification of the effects of test food intake on itchy skin

Acronym

Verification of the effects of test food intake on itchy skin

Scientific Title

Verification of the effects of test food intake on itchy skin
: Placebo-controlled, double-blind, randomized, parallel-group comparison study

Scientific Title:Acronym

Verification of the effects of test food intake on itchy skin
: Placebo-controlled, double-blind, randomized, parallel-group comparison study

Region

Japan


Condition

Condition

Healthy adults

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Ingest the test food for 4 weeks and verify the effect on the immune index during exercise.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Visual Analogue Scale

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Ingestion of test food for 8 weeks

Interventions/Control_2

Ingestion of placebo food for 8 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

64 years-old >=

Gender

Male and Female

Key inclusion criteria

(1) Subjects of men and women aged 20 to 64
(2) Subject suffering from itchy and dry skin
(3) Subjects who received sufficient explanation about the purpose and content of the test, had the ability to consent, voluntarily volunteered to participate after understanding it well, and agreed to participate in the test in writing.

Key exclusion criteria

(1) Subjects with skin diseases (e.g. atopic dermatitis) according to physician's findings
(2) Subjects with diabetes mellitus, liver disease, renal disease, gastrointestinal disease, cardiac disease, respiratory disease, peripheral vascular disease, disease affecting the secretion of adrenal corticosteroids, or other serious diseases, or with pre-existing diseases.
(3) Subjects who have undergone gastrointestinal surgery
(4) Subjects with diseases currently being treated, or for whom treatment is deemed necessary by the principal investigator or research assistants.
(5) Subjects who are allergic to food (especially gelatin) and drugs
(6) Female subjects wishing to become pregnant while participating in this study, pregnant (including those who may be pregnant) or lactating female subjects.
(7) Subjects who habitually engage in strenuous sports such as marathon running (including professional athletes) and subjects on a diet
(8) Subjects with extremely irregular eating habits
(9) Subjects who may be exposed to excessive ultraviolet light during the study period.
(10) Subjects who visit beauty salons for skin care
(11) Subjects who are unable to discontinue consumption of health foods (including food for specified health uses, functional foods, and supplements) and designated quasi-drugs during the study period.
(12) Subjects who continue to receive treatment with drugs (including OTC and prescription drugs, e.g., antihistamines, antiallergic agents, cold remedies, topical steroids, etc.) that affect immunity or skin itching or that affect the results of the study (e.g., hypo sensitization therapy)
(13) Subjects who have a habit of consuming foods rich in acetic acid bacteria (nigori vinegar, etc.), foods rich in lactic acid bacteria or bifidobacteria (lactic acid bacteria drinks, yogurt, kimchi, etc.), or lactic acid bacteria preparations at least 3 times a week.


(14) to (20) are listed in the "Other related information" column.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Naoki
Middle name
Last name Miura

Organization

Miura Clinic, Medical Corporation Kanonkai

Division name

Internal medicine

Zip code

5300044

Address

Higashitenma building 9F, 1-7-17, Higashitenma, Kita-ku, Osaka

TEL

06-6135-5200

Email

info@miura-cl.jp


Public contact

Name of contact person

1st name Makoto
Middle name
Last name Terashima

Organization

Oneness Support Co., Ltd.

Division name

Clinical Trial Division

Zip code

5300044

Address

Higashitenma building 4F, 1-7-17, Higashitenma, Kita-ku, Osaka

TEL

06-4801-8917

Homepage URL


Email

mterashima@oneness-sup.co.jp


Sponsor or person

Institute

Miura Clinic, Medical Corporation Kanonkai

Institute

Department

Personal name



Funding Source

Organization

Kewpie Corporation

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The Ethics Committee of Miura Clinic, Medical Corporation Kanonkai

Address

Higashitenma building 9F, 1-7-17, Higashitenma, Kita-ku, Osaka

Tel

06-6135-5200

Email

mterashima@miura-cl.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人花音会みうらクリニック(大阪府)


Other administrative information

Date of disclosure of the study information

2023 Year 12 Month 07 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2023 Year 11 Month 08 Day

Date of IRB

2023 Year 11 Month 30 Day

Anticipated trial start date

2024 Year 01 Month 15 Day

Last follow-up date

2024 Year 04 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

"Key exclusion sriteria"
(14) Subjects who work day and night shifts or engage in physical labor such as heavy lifting
(15) Subjects who are unable to perform the testing procedures to be conducted during the study period as specified (e.g., questionnaire responses)
(16) Subjects who plan to travel abroad during the research period
(17) Subjects who drink more than 20 g of average daily pure alcohol
(18) Subjects who smoke an average of 21 or more cigarettes per day
(19) Subjects who are participating in or will participate in other clinical trials at the start of this study.
(20) Other subjects judged by the investigator or the investigator to be inappropriate for the examination


Management information

Registered date

2023 Year 12 Month 05 Day

Last modified on

2024 Year 12 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000060454